granisetron

(redirected from Sancuso)

granisetron

 [gră-nis´ĕ-tron]
an antiemetic used in conjunction with cancer chemotherapy or radiotherapy; administered orally or intravenously as the hydrochloride salt.

granisetron

/gran·is·e·tron/ (gră-nis´ĕ-tron) an antiemetic used in conjunction with cancer chemotherapy or radiotherapy, administered as the hydrochloride salt.

granisetron

[granis′etron]
an antiemetic used in conjunction with cancer chemotherapy or radiotherapy, administered orally or intravenously as the hydrochloride salt.

granisetron

Kytril® Oncology A 5-HT3–serotonin receptor antagonist antiemetic used for Pts receiving chemotherapy–eg, cisplatin, cyclophosphamide Adverse effects Headache–35%, constipation–30%, asthenia, somnolence, diarrhea

Granisetron

A serotonin antagonist drug that blocks the nausea receptors in the small intestine and is used to control sickness and vomiting after surgery and in patients on anticancer chemotherapy. It can be used in children. A brand name is Kytril.

granisetron

a 5-HT3-antagonist with potent antiemetic activity.
References in periodicals archive ?
ProStraken, based in Galashiels in the Borders, have developed Sancuso, a drug for chemotherapy patients which eases symptoms of nausea and vomiting.
Subsequent approval by the US Food and Drug Administration (FDA), ProStrakan plans to market Rapinyl alongside its other oncology support product, Sancuso for the prevention of chemotherapy-induced nausea & vomiting (CINV), which is currently under consideration for approval by the FDA.
PROSTRAKAN, a Borders pharmaceutical group, have signed a distribution agreement in South Korea with LG Life Sciences for Sancuso, a patch to prevent chemotherapy-induced nausea and vomiting.
Watkinson, MBA, PhD, has worked in topical and transdermal drug delivery for twenty-three years and played key roles in the development of Axiron (transdermal testosterone) and Sancuso (transdermal granisetron) while at Acrux and ProStrakan, respectively.
In May 2008, Solasia acquired Asian rights to Sancuso (extended release granisetron transdermal patch) from ProStrakan Group plc.
Our US sales force is already calling on these oncology specialists with our anti-emetic patch, Sancuso, and Fareston will be an excellent complement to our promotional efforts.
In May 2008, Solasia acquired Asia rights to Sancuso (extended release granisetron transdermal patch) from ProStrakan Group plc.
Sancuso is the first and only commercialized extended release granisetron transdermal product.
new drug application (NDA) review and Food and Drug Administration (FDA) approval of SANCUSO Transdermal System.
patent for Sancuso was granted on October 27, 2009 to ProStrakan Group plc who developed and own the worldwide rights to Sancuso.
Now, with the availability of Sancuso, healthcare practitioners, patients and caregivers have a new tool in their toolbox to prevent the debilitating side effects of CINV.
Upon SFDA approval of the application expected in the 1st quarter of 2010, Solasia will initiate Sancuso clinical trials in China through Excel PharmaStudies Inc.